Daily Indian funding roundup & key news - 14th january 2026: RISA Labs raises $11.1 Mn, GreenTech secures INR 30 Cr, Pee Safe bags $32 Mn & more. India's startup ecosystem continued to witness steady momentum in mid-January 2026, with capital flowing across healthtech, renewable energy, construction-tech, and consumer wellness sectors. From Binny Bansal-backed RISA Labs securing fresh funding to GreenTech's clean energy push and Pee Safe's growth capital raise, investor interest remained strong across diverse industries. Alongside funding activity, major strategic moves from Ola Electric and Unacademy highlighted key shifts in India's EV and edtech landscapes. Daily Indian startup funding roundup - 14th january 2026. | Company | Amount | Round | Lead investor(s) | Sector | | RISA Labs | $11.1 Mn | Funding round | Cencora Ventures; Optum Ventures (with participation from Oncology Ventures, Z21 Ventures, John Simon / Ventureforgood & Binny Bansal) | AI-driven healthtech / Cancer care workflow automation | | GreenTech | INR 30 Cr | First funding round (Equity + Debt) | Transition VC | Wind turbine asset management & O&M tech | | HandyPanda | INR 2 Cr | Pre-seed | AJVC (with angel investors including Sankalp Kathuria & family office heads) | Construction-tech / Building materials marketplace | | Pee Safe | $32 Mn | Growth capital | OrbiMed | Women's hygiene & wellness products | Binny Bansal-backed RISA Labs raises $11.1 Mn in funding. RISA Labs, an AI-driven healthtech startup focused on transforming cancer care through its AI operating system for oncology workflows, has raised $11.1 million in a funding round co-led by Cencora Ventures and Optum Ventures, with participation from Oncology Ventures, Z21 Ventures, John Simon's Ventureforgood initiative, and existing backer Binny Bansal. The fresh capital will be used to scale product development, expand deployments with hospitals and cancer care networks, and support customer onboarding across the US healthcare system. GreenTech raises INR 30 Cr led by Transition VC. GreenTech, a technology-driven wind turbine asset management and operations & maintenance company based in Coimbatore, has raised INR 30 crore in its first funding round led entirely by Transition VC, comprising a mix of equity and debt. The funding will support expansion of its global infrastructure, enhancement of predictive maintenance platforms, and scaling of operations across domestic and international wind energy markets. Construction-tech startup HandyPanda raises INR 2 Cr led by AJVC. HandyPanda, a construction-tech startup working to organise the building materials supply ecosystem through a tech-enabled platform, has raised INR 2 crore in pre-seed funding led by early-stage venture capital firm AJVC, with participation from angel investors and family offices. The capital will be deployed towards team expansion, platform development, and strengthening operational capabilities. Pee Safe raises $32 Mn as OrbiMed bets on India's hygiene market. Pee Safe, a leading Indian women's hygiene and wellness brand, has raised $32 million in growth capital from global healthcare-focused investment firm OrbiMed. The round includes both primary capital infusion and secondary share purchases from early investors, reflecting strong investor confidence in India's rapidly expanding hygiene and wellness market. Key business news for 15th january 2026. Ola Electric announces expansion of 4680 Bharat Cell platform. Ola Electric has announced an expansion of its 4680 Bharat Cell platform, making the indigenously developed battery cells more broadly available beyond just electric vehicles. Under the initiative, businesses and startups can now purchase 4680 Bharat Cells or the 1.5 kWh battery packs for use in applications like automotive, drones, humanoids and portable medical equipment, helping accelerate energy innovation across sectors. The company has also rolled out its residential Battery Energy Storage System (BESS) solution branded Ola Shakti, with deliveries beginning soon for multiple configurations. This marks a strategic push to scale the company's core battery technology and support new energy use cases across India. Unacademy plans exit from offline centres. Edtech firm Unacademy has announced plans to exit its company-operated offline coaching centres and transition them into a franchise-led model, as part of a strategic shift to focus on its online learning products. Founder Gaurav Munjal informed staff that the change will allow local operators to run day-to-day centre operations while Unacademy continues to provide academic content, technology and brand support. The move to a franchise model is expected to reduce capital intensity, make operations more asset-light and support cost-efficiency, with the transition set to complete in the coming months. Must have tools for startups - recommended by startuptalky. * Convert Visitors into Leads- SeizeLead * Website Builder SquareSpace * Run your business Smoothly Systeme.io * Stock Images Shutterstock

RISA Labs closes $11.1M Series A to scale AI operating system for oncology nationwide. News provided by. PALO ALTO, Calif., Jan. 13, 2026 /PRNewswire/ - RISA Labs, a company pioneering an AI operating system for oncology, today announced the closing of an $11.1 million Series A funding round. The financing was co-led by Cencora Ventures and Optum Ventures, with participation from Oncology Ventures, Z21 Ventures, and John Simon (co-founder of General Catalyst) via his Ventureforgood investment entity. The funding will accelerate the deployment of RISA's system to cancer clinics, health systems, specialty pharmacies, and infusion networks across the United States, changing how complex oncology workflows are managed end-to-end. In oncology, delays are costly for all stakeholders: patients, practices, payers, and pharma. Addressing this, RISA orchestrates patient access, benefits verification, and prior authorization, turning manual bottlenecks into predictable, high-throughput workflows across the cancer service line. In just nine months, partner institutions have already expanded from initial deployment to second and third workflows, reflecting rapid adoption and operational trust. "In our vision for oncology, there are two sides to every patient's journey: getting them on the right therapy faster and deepening our understanding of the disease for the next patient through data," said Kshitij Jaggi, CEO of RISA Labs. RISA connects directly to a cancer center's electronic medical record (EMR), payer and benefits systems, and other systems of record. A team of AI agents reads, reasons, and acts across these systems, gathering the right data, preparing and submitting authorizations, tracking status, and progressing cases across dozens of payer environments, EMRs and other tools. As forms, rules, or interfaces change, the agents adapt in real time, so workflows stay reliable without constant reprogramming. The AI OS is purpose-built for the realities of cancer care, handling complex payer rules, multi-drug regimens, and disease-specific requirements. Teams manage and configure all of this through BOSS Console, RISA's command control panel for mission-critical institutions. With BOSS Console, each institution can tailor workflows, routing, document conventions, and practice-specific rules so the system behaves like an extension of its own operations. Every AI action is traceable and audit-ready, giving leaders clear visibility into what the system did and why, and how it stays aligned with compliance and clinical standards. RISA is already live at some of the largest oncology practices in the U.S. At one partner site, approximately 80% of administrative staff time has been freed up, denials have been reduced by up to 40%, and first-pass approval rates have reached 97.8%. Patient authorizations are now filed within 24 hours of request and are on track to drop below 2 hours, down from an average 8-day backlog. More than 20 full-time equivalents have been repurposed to higher-value work, increasing both capacity and efficiency across the practice. "BOSS Console is a low-entropy thinking information machine," said Kumar Shivang, CTO of RISA Labs. "Modern oncology has created thousands of potential care paths for every patient. It has become essential to have an intelligent operating system that can absorb this complexity, remove administrative burden, and act as a companion to the most informed clinical decisions." By leveraging AI to confront the looming challenge of a growing patient population, increasingly complex treatment strategies, and a limited supply of oncologists, RISA aims to address the core mathematical problem in modern cancer care. "As the treatments available for oncology patients increase in number and complexity, solutions to help streamline operational processes and enable efficient access to therapy become vital. We look forward to supporting RISA on their next phase of growth," said Jason Dinger, Senior Vice President, Strategic Execution at Cencora. In the coming year, RISA will go deeper in oncology, partnering with ecosystem leaders to expand AI-driven workflows across the full continuum of cancer care. Extending these capabilities to specialty pharmacy operations is the next step, built on the same foundation and configured through BOSS Console. About RISA Labs Founded by Kshitij Jaggi and Kumar Shivang, RISA Labs is the creator of BOSS Console that helps build AI OS for mission-critical institutions. Its first area of focus is oncology, where the system unifies access, benefits, and prior authorization across cancer centers, specialty pharmacies, and infusion networks so every eligible patient can start the right therapy faster. Already deployed at leading oncology networks and community practices, RISA helps them operate with greater efficiency, capacity, and precision while strengthening financial performance: making institutions win in the age of AI. For more information, please visit Risa Labs at https://www.risalabs.ai Cencora Ventures is the dedicated corporate venture capital fund of Cencora. Cencora is a leading global pharmaceutical solutions organization centered on improving the lives of people and animals around the world. We partner with pharmaceutical innovators across the value chain to facilitate and optimize market access to therapies. Care providers depend on us for the secure, reliable delivery of pharmaceuticals, healthcare products, and solutions. Our 51,000+ worldwide team members contribute to positive health outcomes through the power of our purpose: We are united in our responsibility to create healthier futures. Cencora is ranked #10 on the Fortune 500 and #18 on the Global Fortune 500 with more than $300 billion in annual revenue. SOURCE RISA Labs